Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection
Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product.
- Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product.
- The new product broadens Fresenius Kabi’s radiology portfolio and is available immediately in the United States.
- Fresenius Kabi Sincalide for Injection is the third product added to the company’s radiology portfolio , an area the company entered last year.
- Fresenius Kabi Sincalide for Injection is preservative-free, and the container closure is not made with natural rubber latex.